Biofidelity, a revolutionary genomic technology company dedicated to bringing the benefits of precision medicine to patients around the world, successfully completed a financing round totaling $24 million bringing total funding raised since the Company was founded in 2019 to $60 million.

The new funding round includes fresh commitments from current investors including Agilent Technologies, Octopus Ventures, BlueYard Capital, and Longwall Ventures.